CSL.AX
CSL Limited
Health Care · Biotechnology · ASX
$97.91
Data: 2026-05-09
✓ ETHICAL PASS
Unknown MOAT
HIGH
Data Confidence: 100.0%
Key Metrics
How this company measures up on the fundamentals that matter
Market Cap
$57.4B
Total market value of the company
Rev Growth
-1.8%
Year-over-year revenue change
Profit Margin
0.0%
How much profit the company keeps from each dollar of revenue
Analyst Target
N/A
Recommendation
N/A
Consensus view from ? analysts covering this stock
About CSL Limited
Company description not available.
Ethical Screening
Five compliance checks based on AAOIFI standards — all must pass for ethical clearance
Business Activity
PASS
Core business does not involve prohibited activities
Debt Ratio
29.2% PASS
Debt must be below 33% of total assets
Cash Ratio
5.5% PASS
Interest-bearing cash below 33% of assets
Receivables
0.5% PASS
Receivables below 49% of assets
Revenue Purity
2.7% PASS
Non-compliant revenue below 5% — any excess requires purification
Valuation
Rating
FAIR VALUE
Overall assessment combining ethics, valuation, and quality
Ethical Score
80.1
Valuation Score
65.5
Quality Score
28.0
Combined
63.4
Trading at $120, 178% above fair value of $43. Passes all ethical screens. Ranks better than 88% of screened stocks.
Quantitative Intelligence
Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data
Annual Return
-39.9%
Historical annualised return based on price data
Days in State
11
How long the current regime has persisted — longer means more stable
Market Data
Trading characteristics and market positioning
N/A
52W High
$N/A
52W Low
$N/A
Avg Volume
N/A
Average daily shares traded — higher means easier to buy and sell
Short % Float
N/A
Financial Health
Balance sheet strength and cash generation — the foundation of long-term value
Quick Ratio
N/A
Like current ratio but excludes inventory — stricter test
Gross Margin
N/A
Revenue left after cost of goods — higher means pricing power
Operating Margin
N/A
Profit from core operations before interest and tax
Revenue (TTM)
N/A
Total revenue over the last 12 months
Net Income
N/A
Loss-making — spending exceeds revenue after all costs
Recent Insider Activity
SEC Form 4 filings — what company insiders are buying and selling
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-15 | Watkins (Alison Mary) | Independent Non-Executive Director | 2,540 | $179,125 | |
| 2026-02-17 | Watkins (Alison Mary) | Independent Non-Executive Director | 214 | — | |
| 2026-02-17 | Cuthbertson (Robert Andrew) | Independent Non-Executive Director | 183 | — | |
| 2026-02-17 | Hewson (Carolyn Judith) | Independent Non-Executive Director | 244 | — | |
| 2026-02-17 | Lewis (Samantha Louise) | Independent Non-Executive Director | 153 | — | |
| 2026-02-17 | McNamee (Brian Anthony) | Independent Non-Executive Director | 433 | — | |
| 2025-12-01 | Naylor (Gordon) | Director | 67,797 | — | |
| 2025-11-18 | Daniels (Brian M.D.) | Non-Independent Executive Director | 3,400 | — | |
| 2025-10-28 | McDonald (Marie) | Former | 723 | — | |
| 2025-10-01 | Price (Cameron Bruce) | Independent Non-Executive Director | 3,296 | — |
Source: SEC Form 4 filings via public data. View all insider activity at
Insider Intelligence
Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-09